Other formats:
BibTeX
LaTeX
RIS
@article{1719057,
author = {Clement, P. and Booth, T. and Borovecki, F. and Emblem, K. E. and Figueiredo, P. and Hirschler, L. and Jančálek, Radim and Keil, V. C. and Maumet, C. and Ozsunar, Y. and Pernet, C. and Petr, J. and Pinto, J. and Smits, M. and Warnert, E. A. H.},
article_location = {HEIDELBERG},
article_number = {2},
doi = {http://dx.doi.org/10.1007/s40846-020-00582-z},
keywords = {Glioma; Advanced MRI; Multi-disciplinary; Networking; Translational research; COST action},
language = {eng},
issn = {1609-0985},
journal = {Journal of Medical and Biological Engineering},
title = {GliMR: Cross-Border Collaborations to Promote Advanced MRI Biomarkers for Glioma},
url = {https://link.springer.com/article/10.1007/s40846-020-00582-z},
volume = {41},
year = {2021}
}
TY - JOUR
ID - 1719057
AU - Clement, P. - Booth, T. - Borovecki, F. - Emblem, K. E. - Figueiredo, P. - Hirschler, L. - Jančálek, Radim - Keil, V. C. - Maumet, C. - Ozsunar, Y. - Pernet, C. - Petr, J. - Pinto, J. - Smits, M. - Warnert, E. A. H.
PY - 2021
TI - GliMR: Cross-Border Collaborations to Promote Advanced MRI Biomarkers for Glioma
JF - Journal of Medical and Biological Engineering
VL - 41
IS - 2
SP - 115-125
EP - 115-125
PB - SPRINGER HEIDELBERG
SN - 16090985
KW - Glioma
KW - Advanced MRI
KW - Multi-disciplinary
KW - Networking
KW - Translational research
KW - COST action
UR - https://link.springer.com/article/10.1007/s40846-020-00582-z
L2 - https://link.springer.com/article/10.1007/s40846-020-00582-z
N2 - Purpose There is an annual incidence of 50,000 glioma cases in Europe. The optimal treatment strategy is highly personalised, depending on tumour type, grade, spatial localization, and the degree of tissue infiltration. In research settings, advanced magnetic resonance imaging (MRI) has shown great promise as a tool to inform personalised treatment decisions. However, the use of advanced MRI in clinical practice remains scarce due to the downstream effects of siloed glioma imaging research with limited representation of MRI specialists in established consortia; and the associated lack of available tools and expertise in clinical settings. These shortcomings delay the translation of scientific breakthroughs into novel treatment strategy. As a response we have developed the network "Glioma MR Imaging 2.0" (GliMR) which we present in this article. Methods GliMR aims to build a pan-European and multidisciplinary network of experts and accelerate the use of advanced MRI in glioma beyond the current "state-of-the-art" in glioma imaging. The Action Glioma MR Imaging 2.0 (GliMR) was granted funding by the European Cooperation in Science and Technology (COST) in June 2019. Results GliMR's first grant period ran from September 2019 to April 2020, during which several meetings were held and projects were initiated, such as reviewing the current knowledge on advanced MRI; developing a General Data Protection Regulation (GDPR) compliant consent form; and setting up the website. Conclusion The Action overcomes the pre-existing limitations of glioma research and is funded until September 2023. New members will be accepted during its entire duration.
ER -
CLEMENT, P., T. BOOTH, F. BOROVECKI, K. E. EMBLEM, P. FIGUEIREDO, L. HIRSCHLER, Radim JANČÁLEK, V. C. KEIL, C. MAUMET, Y. OZSUNAR, C. PERNET, J. PETR, J. PINTO, M. SMITS and E. A. H. WARNERT. GliMR: Cross-Border Collaborations to Promote Advanced MRI Biomarkers for Glioma. \textit{Journal of Medical and Biological Engineering}. HEIDELBERG: SPRINGER HEIDELBERG, 2021, vol.~41, No~2, p.~115-125. ISSN~1609-0985. Available from: https://dx.doi.org/10.1007/s40846-020-00582-z.
|
